The performance of the stock price over the year has been up and down, leaving investors with either an optimistic or pessimistic outlook, depending on how they interpret the data. The index has shown a price loss of -28.70% this year. The price of BCAX leaped by -6.05% during the last 30 days period. For the last 5-days stocks have slided -24.95%.
52-week price history of BCAX Stock
Analyzing a stock’s 52-week high and low prices can offer important information about its present condition and future outlook. Bicara Therapeutics Inc’s current trading price is -55.78% away from its 52-week high, while its distance from the 52-week low is 11.89%. The stock’s price range during this period has varied between$11.10 and $28.09. The Bicara Therapeutics Inc’s shares, which operate in the Healthcare, saw a trading volume of around 0.75 million for the day, a figure considerably higher than their average daily volume of 0.5 million over last three months.
Market Capitalization vs. Financial Performance: A Comparative Study
Bicara Therapeutics Inc (BCAX) has experienced a quarterly decline of -35.65% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 675.84M.
Combining Moving Average and Trading Volume Data for Better Market Insight
Based on Barchart.com data, the company’s moving average over the 100-day period was 17.01, with a change in price of -8.02. Similarly, Bicara Therapeutics Inc recorded 430,651 in trading volume during the last 100 days, posting a change of -39.24%.
BCAX’s Debt-to-Equity Ratio Cause for Concern? An In-Depth Look
The debt-to-equity (D/E) ratio is a significant metric that provides insights into a company’s financial state and market presence. By dividing a company’s current liabilities by its shareholders’ equity, the D/E ratio depicts the extent of debt used by a company to fund its assets relative to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for BCAX stands at 0.00. Similarly, the long-term debt-to-equity ratio is also 0.00.
BCAX Stock Stochastic Average
Bicara Therapeutics Inc’s raw stochastic average for the past 50 days is presently 20.43%, as of today. This marks a increase from the raw stochastic average of the last 20 days, which was 13.33%. Additionally, the company’s Stochastic %K and %D values for the past 20 days were 23.64% and 37.90%, respectively.
